1
|
Betancor D, Barroso B, Valverde-Monge M, Gomez-Lopez A, Sastre J. The discrepancy in bronchodilator response between ATS/ERS 2021 and 1991 criteria. Respir Med 2024; 226:107609. [PMID: 38583814 DOI: 10.1016/j.rmed.2024.107609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2023] [Revised: 03/10/2024] [Accepted: 03/22/2024] [Indexed: 04/09/2024]
Affiliation(s)
- Diana Betancor
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
| | - Blanca Barroso
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - Marcela Valverde-Monge
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - Alicia Gomez-Lopez
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - Joaquin Sastre
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
2
|
Barroso B, Gómez-López A, Valverde-Monge M, Betancor D, de Las Heras M, Sastre J. Hypersensitivity Reactions to the GLP-1 Receptor Agonists Liraglutide and Semaglutide: A Case Series. J Investig Allergol Clin Immunol 2024; 34:133-135. [PMID: 38639450 DOI: 10.18176/jiaci.0932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/20/2024] Open
Affiliation(s)
- B Barroso
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - A Gómez-López
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M Valverde-Monge
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - D Betancor
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - M de Las Heras
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J Sastre
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
3
|
Barroso B, Gómez-López A, Betancor D, Valverde-Monge M, Sastre J. Reply to "European academy of allergy and clinical immunology, food allergy, anaphylaxis guidelines group. EAACI guidelines: Anaphylaxis (2021 update)". Allergy 2024. [PMID: 38214139 DOI: 10.1111/all.16018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2023] [Accepted: 01/03/2024] [Indexed: 01/13/2024]
Affiliation(s)
- Blanca Barroso
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Alicia Gómez-López
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Diana Betancor
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Marcela Valverde-Monge
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Joaquín Sastre
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
4
|
Alobid I, Barroso B, Calvo C, Ferrario MG, Sastre J. Effect of different therapeutic strategies on olfactory outcomes in patients with chronic rhinosinusitis with nasal polyps: a systematic review. J Investig Allergol Clin Immunol 2024; 34:0. [PMID: 38174981 DOI: 10.18176/jiaci.0987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2024] Open
Abstract
INTRODUCTION Olfactory impairment is one of the cardinal symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP), yet the effect of the currently available therapeutic options on the recovery of the sense of smell is not well defined. The aim of this systematic review was to compile the evidence on the impact of medical, surgical, and biological therapies on the olfactory outcomes in patients with CRSwNP. METHODS This review was conducted by two reviewers, according to the Preferred Reporting Items for Systematic Reviews and meta-Analyses (PRISMA) guidelines. The quality of evidence of all studies included in the qualitative synthesis was evaluated using the Critical Appraisal Skills Programme (CASP). RESULTS Forty-four studies were included in the qualitative synthesis (assessing sinonasal surgery [n = 23], biologics [n =15], and conventional medical treatment [n = 6]); most had moderate-to-high methodological quality. Overall, significant improvements in the sense of smell were detected with all analyzed interventions measured by either an objective or a subjective tool (or both). However, most studies used different outcome measurements, hindering comparisons between interventions, and data on clinically relevant changes were missing. CONCLUSION Oral corticosteroids, biologics and sinonasal surgery improve olfactory impairment associated with CRSwNP, but the high variability among existing studies does not allow accurate comparisons.
Collapse
Affiliation(s)
- I Alobid
- Skull Base Unit, ENT Department, Hospital Clinic, IDIBAPS, CIBERES, Barcelona University. Barcelona, Spain
- Unidad Alergo-Rino, Centro Médico Teknon, Barcelona, Spain
| | - B Barroso
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain. CIBERES, Instituto de Salud Carlos III, Spain
| | - C Calvo
- Rhinology and sleep apnea unit, Otolaryngology department, Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain
| | | | - J Sastre
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain. CIBERES, Instituto de Salud Carlos III, Spain
| |
Collapse
|
5
|
Valverde-Monge M, Sánchez-Carrasco P, Betancor D, Barroso B, Rodrigo-Muñoz JM, Mahillo-Fernández I, Arismendi E, Bobolea I, Cárdaba B, Cruz MJ, Del Pozo V, Domínguez-Ortega J, González-Barcala FJ, Olaguibel JM, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Peleteiro-Pedraza L, Picado Valles C, Plaza V, Quirce S, Rial MJ, Soto-Retes L, Valero A, Sastre J. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients. Arch Bronconeumol 2024; 60:23-32. [PMID: 38042707 DOI: 10.1016/j.arbres.2023.11.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Revised: 11/18/2023] [Accepted: 11/20/2023] [Indexed: 12/04/2023]
Abstract
BACKGROUND Evaluation of biologic therapy response is vital to monitor its effectiveness. Authors have proposed various response criteria including good responder, super-responder, non-responder, and clinical remission. OBJECTIVES To ascertain the prevalence of response and clinical remission after long-term treatment (>6 months) of anti-IgE and anti-IL-5/IL-5Rα biologics, compare these results with existing criteria, and identify predictors for non-responders and clinical remission. METHODS A multicenter, real-life study involving severe asthma patients in Spain. Various outcomes were assessed to gauge response and clinical remission against established criteria. RESULTS The study included 429 patients, 209 (48.7%) omalizumab, 112 (26.1%) mepolizumab, 19 (4.4%) reslizumab and 89 (20.7%) benralizumab, with a mean treatment duration of 55.3±38.8 months. In the final year of treatment, 218 (50.8%) were super-responders, 173 (40.3%) responders, 38 (8.9%) non-responders, and clinical remission in 116 (27%), without differences among biologics. The short-term non-responders (<6 months) were 25/545 (4.6%). Substantial variations in response and clinical remission were observed when applying different published criteria. Predictors of non-response included higher BMI (OR:1.14; 95% CI:1.06-1.23; p<0.001), admissions at ICU (2.69; 1.30-5.56; p=0.01), high count of SAE (1.21; 1.03-1.42; p=0.02) before biologic treatment. High FEV1% (0.96; 0.95-0.98; p<0.001), a high ACT score (0.93; 0.88-0.99; p=0.01) before biologic treatment or NSAID-ERD (0.52; 0.29-0.91; p=0.02) showed strong associations with achieving clinical remission. CONCLUSION A substantial proportion of severe asthma patients treated long-term with omalizumab or anti-IL5/IL-5Rα achieved a good response. Differences in response criteria highlight the need for harmonization in defining response and clinical remission in biologic therapy to enable meaningful cross-study comparisons.
Collapse
Affiliation(s)
- Marcela Valverde-Monge
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
| | | | - Diana Betancor
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Blanca Barroso
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - José Manuel Rodrigo-Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Immunology Department, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Ignacio Mahillo-Fernández
- Epidemiology and Biostatistics Department, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Ebymar Arismendi
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain; IDIBAPS, Barcelona, Spain; Universitat de Barcelona, Barcelona, Spain
| | - Irina Bobolea
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain; IDIBAPS, Barcelona, Spain; Universitat de Barcelona, Barcelona, Spain
| | - Blanca Cárdaba
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Immunology Department, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - María Jesús Cruz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Cellular Biology, Physiology and Immunology Department, Universitat Autónoma de Barcelona, Barcelona, Spain; Pneumology Department, Hospital Vall d'Hebron, Barcelona, Spain
| | - Victoria Del Pozo
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Faculty of Medicine, Universidad Autónoma de Madrid, Spain; Immunology Department, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Javier Domínguez-Ortega
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Pneumology Department, Hospital Vall d'Hebron, Barcelona, Spain
| | - Francisco Javier González-Barcala
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Pneumology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
| | - José María Olaguibel
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Allergy Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
| | - Juan Alberto Luna-Porta
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Allergy Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - Carlos Martínez-Rivera
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Pneumology Department, Hospital Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Badalona, Barcelona, Spain; Universitat Autónoma de Barcelona, Spain
| | - Joaquim Mullol
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Universitat de Barcelona, Barcelona, Spain; Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain; Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain
| | - Xavier Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Pneumology Department, Hospital Vall d'Hebron, Barcelona, Spain
| | - Lorena Peleteiro-Pedraza
- Pneumology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
| | - Cesar Picado Valles
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain; IDIBAPS, Barcelona, Spain; Universitat de Barcelona, Barcelona, Spain
| | - Vicente Plaza
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Pneumology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain; Departamento de Medicina, Universidad de Autónoma, Barcelona, Spain
| | - Santiago Quirce
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Allergy Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - Manuel Jorge Rial
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Allergy Department, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - Lorena Soto-Retes
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Pneumology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain; Departamento de Medicina, Universidad de Autónoma, Barcelona, Spain
| | - Antonio Valero
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain; IDIBAPS, Barcelona, Spain; Universitat de Barcelona, Barcelona, Spain
| | - Joaquín Sastre
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; Faculty of Medicine, Universidad Autónoma de Madrid, Spain
| |
Collapse
|
6
|
Betancor D, Otal M, Olaguibel JM, Rodrigo-Muñoz JM, Alvarez Puebla JM, Arismendi E, Barranco P, Barroso B, Bobolea I, Cárdaba B, Cruz MJ, Curto E, Del Pozo V, Domínguez-Ortega J, González-Barcala FJ, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Picado C, Plaza V, Quirce S, Rial MJ, Roibás-Veiga I, Soto-Retes L, Valero A, Valverde-Monge M, Sastre J. Global Lung Initiative as diagnostic criteria in Asthma-COPD overlap syndrome. Prevalence and characterization of the syndrome in a real-life asthma cohort. J Investig Allergol Clin Immunol 2023; 34:0. [PMID: 38131661 DOI: 10.18176/jiaci.0966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023] Open
Affiliation(s)
- D Betancor
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M Otal
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J M Olaguibel
- Servicio de Alergología, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - J M Rodrigo-Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria del Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J M Alvarez Puebla
- Servicio de Alergología, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - E Arismendi
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic; Universitat de Barcelona, Barcelona, Spain
| | - P Barranco
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, Madrid, Spain
| | - B Barroso
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - I Bobolea
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic; Universitat de Barcelona, Barcelona, Spain
| | - B Cárdaba
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria del Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M J Cruz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Departamento de Biología Celular, Fisiología e Inmunología, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - E Curto
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - V Del Pozo
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria del Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J Domínguez-Ortega
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, Madrid, Spain
| | - F J González-Barcala
- Department of Respiratory Medicine, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
| | - J A Luna-Porta
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, Madrid, Spain
| | - C Martínez-Rivera
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Neumología, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - J Mullol
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Rhinology Unit & Smell Clinic, ENT Department; Universitat de Barcelona. Barcelona, Spain
| | - X Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Neumología, Hospital Vall d'Hebron, Barcelona, Spain
| | - C Picado
- Pneumonology and Allergy Department, Hospital Clínic; Universitat de Barcelona, Barcelona, Spain
| | - V Plaza
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - S Quirce
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, Madrid, Spain
| | - M J Rial
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergología, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - I Roibás-Veiga
- Servicio de Alergia. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - L Soto-Retes
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - A Valero
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic; Universitat de Barcelona, Barcelona, Spain
| | - M Valverde-Monge
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - J Sastre
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
7
|
Betancor D, Valverde-Monge M, Barroso B, Gomez-Lopez A, Sastre J. Non-asthmatic eosinophilic bronquitis review. A systematic review of current treatment options. J Investig Allergol Clin Immunol 2023; 34:0. [PMID: 38113129 DOI: 10.18176/jiaci.0984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2023] Open
Abstract
Non-asthmatic eosinophilic bronchitis is characterized by persistent dry or less productive cough and bronchial eosinophilia without airway obstruction or bronchial hyperreactivity. It is primarily a chronic disease in which some patients have clinical and pathophysiological relapses while others progress to asthma or chronic obstructive pulmonary disease. It accounts for 5 to 30% of cases referred for chronic cough. Exposure to common inhalants and occupational sensitizers has been proposed as a possible cause of the disease, but its etiology and underlying mechanisms are uncertain. Some features were similar to those of asthma, such as airway eosinophilia, level of inflammatory mediators and airway remodeling. Nevertheless, there are differences in airway pathophysiology, such as the location of airway inflammation and levels of IL-13 and PGE-2. Sputum cell count is the “gold standard” test for diagnosis, and other biomarkers, such as exhaled nitric oxide, could support the diagnosis. A systematic review of treatments for the disease has been done. Although inhaled corticosteroids are the primary treatment, the accurate dose, the kind of corticosteroid, and the treatment time remain unknown. Treatment duration is inversely correlated with relapse rate. Increased doses of inhaled corticosteroids, oral corticosteroids and leukotriene receptor antagonists are recommended in perseverance disease. Anti IL-5 biologic could be promising in this disease. There is a requirement for studies that investigate biomarkers for diagnosis and prognosis and randomized controlled studies for second-line treatments.
Collapse
Affiliation(s)
- D Betancor
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M Valverde-Monge
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - B Barroso
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - A Gomez-Lopez
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J Sastre
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| |
Collapse
|
8
|
Barroso B, Gómez-López A, Valverde-Monge M. Reply to "Management of Patients with Suspected or Confirmed Antibiotic Allergy". J Investig Allergol Clin Immunol 2023; 33:500-501. [PMID: 36912014 DOI: 10.18176/jiaci.0901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/12/2023] Open
Affiliation(s)
- B Barroso
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - A Gómez-López
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M Valverde-Monge
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
9
|
Barroso B, Valverde-Monge M, Betancor D, Gómez-López A, Villalobos-Vilda C, González-Cano B, Sastre J. Improvement in Smell Using Monoclonal Antibodies Among Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review. J Investig Allergol Clin Immunol 2023; 33:419-430. [PMID: 37669083 DOI: 10.18176/jiaci.0939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/06/2023] Open
Abstract
BACKGROUND Impairment of smell is more commonly related to chronic rhinosinusitis with nasal polyps (CRSwNP) than without, especially when asthma and/or NSAID-exacerbated respiratory disease and type 2 inflammation are also present. Therapeutic options include intranasal and systemic corticosteroids, surgery, and, more recently, biological therapy. We summarize current knowledge on the effect of biologics on olfaction in patients with CRSwNP. METHODS We performed a systematic search of the PubMed and Cochrane databases from January 2001 to June 2022. The inclusion criteria were as follows: adult patients with CRS treated with dupilumab, omalizumab, mepolizumab, benralizumab, or reslizumab; and studies published in English reporting outcomes for sense of smell based on psychophysical and/or subjective tools. We excluded reports that did not assess CRSwNP, loss of smell evaluated with a method other than those accepted in the inclusion criteria, review articles, and expert opinions. No funding was received. RESULTS Dupilumab has demonstrated rapid and sustained long-term improvement in smell in clinical trials and in real life. Omalizumab improves smell at 24 weeks. This improvement is maintained in the long-term, although it is not clinically relevant. Mepolizumab and benralizumab improved smell in the long term based on a subjective scale. No studies examining the improvement in smell in patients with CRSwNP treated with reslizumab were found. Indirect comparisons by meta-analysis consistently conclude that dupilumab is the most effective biologic for improving impaired sense of smell. CONCLUSION Dupilumab seems to be more efficacious for improving the sense of smell than omalizumab, mepolizumab, and benralizumab.
Collapse
Affiliation(s)
- B Barroso
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - M Valverde-Monge
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - D Betancor
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - A Gómez-López
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - C Villalobos-Vilda
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - B González-Cano
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J Sastre
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
10
|
Barroso B, Valverde-Monge M, Alobid I, Olaguibel JM, Rial MJ, Quirce S, Arismendi E, Barranco P, Betancor D, Bobolea I, Cárdaba B, Cruz Carmona MJ, Curto E, Domínguez-Ortega J, González-Barcala FJ, Martínez-Rivera C, Mahíllo-Fernández I, Muñoz X, Picado C, Plaza V, Rodrigo Muñoz JM, Soto-Retes L, Valero A, Del Pozo V, Mullol J, Sastre J. Reply to "Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies". J Investig Allergol Clin Immunol 2023; 33:503-504. [PMID: 38095497 DOI: 10.18176/jiaci.0953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2023] Open
Affiliation(s)
- B Barroso
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - M Valverde-Monge
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - I Alobid
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
| | - J M Olaguibel
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Allergy Department, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - M J Rial
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Allergy Department, Hospital Juan Canalejo, A Coruña, Spain
| | - S Quirce
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - E Arismendi
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - P Barranco
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - D Betancor
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - I Bobolea
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - B Cárdaba
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - M J Cruz Carmona
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - E Curto
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - J Domínguez-Ortega
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - F J González-Barcala
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
| | - C Martínez-Rivera
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology Department, Hospital Germans Trias i Pujol, Badalona, Spain
| | | | - X Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - C Picado
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Plaza
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - J M Rodrigo Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - L Soto-Retes
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - A Valero
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Del Pozo
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - J Mullol
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain
- Clinical and Experimental Respiratory Immunoallergy, FRCB-IDIBAPS, Barcelona, Spain
| | - J Sastre
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
11
|
Romero-Mesones C, Cruz MJ, Alobid I, Barroso B, Arismendi E, Barranco P, Betancor D, Bobolea I, Cárdaba B, Curto E, Domenech G, Domínguez-Ortega J, Espejo D, González-Barcala FJ, Luna-Porta JA, Martínez-Rivera C, Méndez-Brea P, Mullol J, Olaguibel JM, Picado C, Plaza V, Del Pozo V, Quirce S, Rial MJ, Rodrigo-Muñoz JM, Sastre J, Serrano S, Soto-Retes L, Valero A, Valverde-Monge M, Munoz X. Disposition of Work-Related Asthma in a Spanish Asthma Cohort: Comparison of Asthma Severity Between Employed and Retired Workers. J Allergy Clin Immunol Pract 2023; 11:3407-3413.e1. [PMID: 37391017 DOI: 10.1016/j.jaip.2023.06.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Revised: 06/14/2023] [Accepted: 06/15/2023] [Indexed: 07/02/2023]
Abstract
BACKGROUND Exposure to certain agents in the workplace can trigger occupational asthma or work-exacerbated asthma, both of which come under the heading of work-related asthma (WRA). Understanding the burden that WRA represents can help in the management of these patients. OBJECTIVE To assess the influence of occupation on asthma in real life and analyze the characteristics of patients with WRA included in an asthma cohort. METHODS This was a prospective multicenter study of a cohort of consecutive patients with asthma. A standardized clinical history was completed. Patients were classified as having WRA or non-WRA. All patients underwent respiratory function tests, FeNO test, and methacholine challenge (methacholine concentration that causes a 20% drop in FEV1) at the beginning of the study. They were classified into two groups, depending on their employment status: employed (group 1) or unemployed (group 2). RESULTS Of the 480 patients included in the cohort, 82 (17%) received the diagnosis of WRA. Fifty-seven patients (70%) were still working. Mean age (SD) was 46 (10.69) years in group 1 and 57 (9.91) years in group 2 (P < .0001). Significant differences were observed in adherence to treatment (64.9% in group 1 vs 88% in group 2; P = .0354) and in severe asthma exacerbations (35.7% in group 1 vs 0% in group 2; P = .0172). No significant differences were observed in the rest of the variables analyzed. CONCLUSIONS The burden of WRA in specialized asthma units is not negligible. The absence of differences in the severity of asthma, the treatment administered, alterations in lung function, and the number of exacerbations in those working versus not working may support the idea that advice regarding changing jobs should be customized for individual patients.
Collapse
Affiliation(s)
- Christian Romero-Mesones
- Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain; CIBER de Enfermedades Respiratorias, Madrid, Spain
| | - Maria-Jesus Cruz
- Servicio de Neumología. Hospital Universitario Vall d'Hebron, Barcelona, Spain; Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain; CIBER de Enfermedades Respiratorias, Madrid, Spain.
| | - Isam Alobid
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic Barcelona, Universitat de Barcelona, Barcelona, Spain; Clinical and Experimental Respiratory Immunoallergy, Instituto de Investigaciones Biomédicas August Pi i Sunyer, Barcelona, Spain
| | - Blanca Barroso
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Ebymar Arismendi
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | - Pilar Barranco
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain
| | - Diana Betancor
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Irina Bobolea
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | - Blanca Cárdaba
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz-Universidad Autónoma de Madrid, Madrid, Spain
| | - Elena Curto
- CIBER de Enfermedades Respiratorias, Madrid, Spain
| | - Gemma Domenech
- Medical Statistics Core Facility, Instituto de Investigaciones Biomédicas August Pi i Sunyer, Hospital Clinic Barcelona, Barcelona, Spain
| | - Javier Domínguez-Ortega
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain
| | - David Espejo
- Servicio de Neumología. Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | | | - Juan-Alberto Luna-Porta
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain
| | - Carlos Martínez-Rivera
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Pulmonology Department, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona Badalona, Barcelona, Spain
| | - Paula Méndez-Brea
- Allergy Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain
| | - Joaquim Mullol
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Rhinology Unit and Smell Clinic, ENT Department, Clinical and Experimental Respiratory Immunoallergy (Instituto de Investigaciones Biomédicas August Pi i Sunyer), Universitat de Barcelona, Barcelona, Spain
| | | | - Cesar Picado
- Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic Barcelona, Universitat de Barcelona, Barcelona, Spain; Clinical and Experimental Respiratory Immunoallergy, Instituto de Investigaciones Biomédicas August Pi i Sunyer, Barcelona, Spain
| | - Vicente Plaza
- Servicio de Neumología y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Victoria Del Pozo
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz-Universidad Autónoma de Madrid, Madrid, Spain
| | - Santiago Quirce
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain
| | - Manuel-Jorge Rial
- Allergy Department, Complexo Hospitalario Universitario, A Coruña, Spain
| | - José-María Rodrigo-Muñoz
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz-Universidad Autónoma de Madrid, Madrid, Spain
| | - Joaquin Sastre
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Sandra Serrano
- Medical Statistics Core Facility, Instituto de Investigaciones Biomédicas August Pi i Sunyer, Hospital Clinic Barcelona, Barcelona, Spain
| | - Lorena Soto-Retes
- Servicio de Neumología y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Antonio Valero
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | - Marcela Valverde-Monge
- CIBER de Enfermedades Respiratorias, Madrid, Spain; Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Xavier Munoz
- Servicio de Neumología. Hospital Universitario Vall d'Hebron, Barcelona, Spain; Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain; CIBER de Enfermedades Respiratorias, Madrid, Spain
| |
Collapse
|
12
|
Betancor D, Gomez-Lopez A, Nuñez-Borque E, Fernandez-Bravo S, Barroso B, Esteban V, Pastor-Vargas C, Cuesta-Herranz J. Allergy to Persimmon (Diospyros kaki), A Chitinase and Thaumatin-Like Protein: 2 Newly Identified Allergens. J Investig Allergol Clin Immunol 2023; 33:412-414. [PMID: 36748361 DOI: 10.18176/jiaci.0886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Affiliation(s)
- D Betancor
- Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain
| | - A Gomez-Lopez
- Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain
| | - E Nuñez-Borque
- Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain
| | - S Fernandez-Bravo
- Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain
- Red de asma, reacciones adversas y alérgicas (ARADyAL) RD16/0006/0013, Instituto de Salud Carlos III, Madrid, Spain
| | - B Barroso
- Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain
| | - V Esteban
- Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain
- Red de asma, reacciones adversas y alérgicas (ARADyAL) RD16/0006/0013, Instituto de Salud Carlos III, Madrid, Spain
| | - C Pastor-Vargas
- Red de asma, reacciones adversas y alérgicas (ARADyAL) RD16/0006/0013, Instituto de Salud Carlos III, Madrid, Spain
- Department of Biochemistry and Molecular Biology, Universidad Complutense de Madrid, Madrid, Spain
| | - J Cuesta-Herranz
- Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain
- Red de asma, reacciones adversas y alérgicas (ARADyAL) RD16/0006/0013, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
13
|
Betancor D, Villalobos-Vilda C, Olaguibel JM, Rodrigo-Muñoz JM, Puebla MJA, Arismendi E, Barranco P, Barroso B, Bobolea I, Cárdaba B, Cruz MJ, Curto E, Pozo VD, Domínguez-Ortega J, González-Barcala FJ, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Picado C, Plaza V, Quirce S, Rial MJ, Soto-Retes L, Valero A, Valverde-Monge M, Sastre J. The New ERS/ATS 2022 Bronchodilator Response Recommendation: Comparison With the Previous Version in an Asthma Cohort. Arch Bronconeumol 2023; 59:608-611. [PMID: 37331901 DOI: 10.1016/j.arbres.2023.05.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Revised: 05/22/2023] [Accepted: 05/23/2023] [Indexed: 06/20/2023]
Affiliation(s)
- Diana Betancor
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
| | | | - José María Olaguibel
- Servicio de Alergología, Hospital Universitario de Navarra, Pamplona, Navarra, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - José Manuel Rodrigo-Muñoz
- Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - María Jose Alvarez Puebla
- Servicio de Alergología, Hospital Universitario de Navarra, Pamplona, Navarra, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Ebymar Arismendi
- Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Pilar Barranco
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Blanca Barroso
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Irina Bobolea
- Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Blanca Cárdaba
- Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - María Jesús Cruz
- Departamento de Biología Celular, Fisiología e Inmunología, Universitat Autónoma de Barcelona, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Elena Curto
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Departamento de Medicina, Barcelona, Spain
| | - Victoria Del Pozo
- Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Javier Domínguez-Ortega
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | | | - Juan Alberto Luna-Porta
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Carlos Martínez-Rivera
- Servicio de Neumología, Hospital Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Badalona, Barcelona, Spain; Universitat Autònoma de Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Joaquim Mullol
- Rhinology Unit & Smell Clinic, ENT Department, Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Universitat de Barcelona, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Xavier Muñoz
- Servicio de Neumología, Hospital Vall d'Hebron, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Cesar Picado
- Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
| | - Vicente Plaza
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Departamento de Medicina, Barcelona, Spain
| | - Santiago Quirce
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Manuel Jorge Rial
- Servicio de Alergología, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Lorena Soto-Retes
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Departamento de Medicina, Barcelona, Spain
| | - Antonio Valero
- Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Marcela Valverde-Monge
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Joaquín Sastre
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
14
|
Betancor D, Olaguibel JM, Rodrigo-Muñoz JM, Alvarez Puebla MJ, Arismendi E, Barranco P, Barroso B, Bobolea I, Cárdaba B, Cruz MJ, Curto E, Del Pozo V, Domínguez-Ortega J, González-Barcala FJ, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Picado C, Plaza V, Quirce S, Rial MJ, Soto-Retes L, Valero A, Valverde-Monge M, Sastre J. Lung Function Abnormalities and Their Correlation With Clinical Characteristics and Inflammatory Markers in Adult Asthma. J Investig Allergol Clin Immunol 2023; 33:294-296. [PMID: 36331127 DOI: 10.18176/jiaci.0866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/28/2023] Open
Affiliation(s)
- D Betancor
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J M Olaguibel
- Servicio de Alergología, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - J M Rodrigo-Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M J Alvarez Puebla
- Servicio de Alergología, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - E Arismendi
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Universitat de Barcelona. Barcelona, Spain
| | - P Barranco
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - B Barroso
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - I Bobolea
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Universitat de Barcelona. Barcelona, Spain
| | - B Cárdaba
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M J Cruz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Departamento de Biología Celular, Fisiología e Inmunología, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - E Curto
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - V Del Pozo
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J Domínguez-Ortega
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - F J González-Barcala
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
| | - J A Luna-Porta
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - C Martínez-Rivera
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Neumología, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - J Mullol
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Universitat de Barcelona. Barcelona, Spain
- Rhinology Unit and Smell Clinic, ENT Department Hospital Clínic, Barcelona, Spain
| | - X Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Neumología, Hospital Vall d'Hebron, Barcelona, Spain
| | - C Picado
- Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Plaza
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - S Quirce
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergia, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - M J Rial
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Servicio de Alergología, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - L Soto-Retes
- Servicio de Neumologia y Alergia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - A Valero
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
- Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - M Valverde-Monge
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - J Sastre
- Servicio de Alergología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
15
|
Domínguez-Ortega J, Luna-Porta JA, Olaguibel JM, Barranco P, Arismendi E, Barroso B, Betancor D, Bobolea I, Caballero ML, Cárdaba B, Cruz MJ, Curto E, González-Barcala FJ, Losantos-García I, Martínez-Rivera C, Mendez-Brea P, Mullol J, Muñoz X, Picado C, Plaza V, Del Pozo V, Rial MJ, Sastre J, Soto L, Valero A, Valverde-Monge M, Quirce S. Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity. J Investig Allergol Clin Immunol 2023; 33:281-288. [PMID: 35503227 DOI: 10.18176/jiaci.0816] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/28/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Comorbidities can influence asthma control and promote asthma exacerbations (AEs). However, the impact of multimorbidity in AEs, assessed based on long-term follow-up of patients with asthma of different degrees of severity, has received little attention in real-life conditions. To describe the epidemiological and clinical characteristics and predictors of AEs in patients who had presented at least 1 AE in the previous year in the MEchanism of Genesis and Evolution of Asthma (MEGA) cohort. METHODS The work-up included a detailed clinical examination, pulmonary function testing, fractional exhaled nitric oxide (FeNO), blood counts, induced sputum, skin prick-tests, asthma questionnaires, and assessment of multimorbidity. The number of moderate-severe AEs in the preceding year was registered for each patient. RESULTS The study population comprised 486 patients with asthma (23.7% mild, 35% moderate, 41.3% severe). Disease remained uncontrolled in 41.9%, and 47.3% presented ≥1 moderate-severe AE, with a mean (SD) annual exacerbation rate of 0.47 (0.91) vs 2.11 (2.82) in mild and severe asthma, respectively. Comorbidity was detected in 56.4% (66.6% among those with severe asthma). Bronchiectasis, chronic rhinosinusitis with nasal polyps, atopy, psychiatric illnesses, hyperlipidemia, and hypertension were significantly associated with AEs. No associations were found for FeNO, blood eosinophils, or total serum IgE. Sputum eosinophilia and a high-T2 inflammatory pattern were significantly associated with AEs. Multivariable regression analysis showed a significant association with asthma severity, uncontrolled disease, and low prebronchodilator FEV1/FVC. CONCLUSION Our study revealed a high frequency of AE in the MEGA cohort. This was strongly associated with multimorbidity, asthma severity, poor asthma control, airflow obstruction, higher sputum eosinophils, and a very high-T2 inflammatory pattern.
Collapse
Affiliation(s)
- J Domínguez-Ortega
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Institute for Health Research IdiPAZ, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - J A Luna-Porta
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Institute for Health Research IdiPAZ, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - J M Olaguibel
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Severe Asthma Unit, Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - P Barranco
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Institute for Health Research IdiPAZ, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - E Arismendi
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - B Barroso
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - D Betancor
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - I Bobolea
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - M L Caballero
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Institute for Health Research IdiPAZ, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - B Cárdaba
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Immunology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M J Cruz
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Departamento de Biología Celular, Fisiología e Inmunología, Universitat Autónoma de Barcelona, Barcelona, Spain
- Pneumology Department, Hospital Vall d'Hebron, Barcelona, Spain
| | - E Curto
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Respiratory Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Barcelona, Spain
- Universidad Autónoma de Barcelona, Departamento de Medicina, Barcelona, Spain
| | - F J González-Barcala
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Pneumology Department, Complejo Hospitalario Universitario de Santiago, La Coruña, Spain
- Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), La Coruña, Spain
- Universidad de Santiago de Compostela, La Coruña, Spain
| | - I Losantos-García
- Institute for Health Research IdiPAZ, Madrid, Spain
- Biostatistics Department, La Paz University Hospital, Madrid, Spain
| | - C Martínez-Rivera
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Universidad Autónoma de Barcelona, Departamento de Medicina, Barcelona, Spain
- Pneumology Department, Hospital Germans Trias i Pujol, Barcelona, Spain
- Institut d'Investigacio Germans Trias I Pujol (IGTP), Badalona, Barcelona, Spain
| | - P Mendez-Brea
- Department of Allergy, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
| | - J Mullol
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
- Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain
| | - X Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Pneumology Department, Hospital Vall d'Hebron, Barcelona, Spain
| | - C Picado
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Plaza
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Respiratory Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Barcelona, Spain
- Universidad Autónoma de Barcelona, Departamento de Medicina, Barcelona, Spain
| | - V Del Pozo
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Immunology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M J Rial
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Allergy, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - J Sastre
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - L Soto
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Respiratory Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Barcelona, Spain
- Universidad Autónoma de Barcelona, Departamento de Medicina, Barcelona, Spain
| | - A Valero
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Clinical and Experimental Respiratory Immunoallergy (IDIBAPS), Barcelona, Spain
- Universitat de Barcelona, Barcelona, Spain
- Allergy Unit and Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - M Valverde-Monge
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - S Quirce
- Department of Allergy, La Paz University Hospital, Madrid, Spain
- Institute for Health Research IdiPAZ, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
16
|
Barroso B, Valverde-Monge M, Alobid I, Olaguibel JM, Rial MJ, Quirce S, Arismendi E, Barranco P, Betancor D, Bobolea I, Cárdaba B, Cruz Carmona MJ, Curto E, Domínguez-Ortega J, González-Barcala FJ, Martínez-Rivera C, Mahíllo-Fernández I, Muñoz X, Picado C, Plaza V, Rodrigo Muñoz JM, Soto-Retes L, Valero A, Del Pozo V, Mullol J, Sastre J. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study. J Investig Allergol Clin Immunol 2023; 33:37-44. [PMID: 35416154 DOI: 10.18176/jiaci.0812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND AND OBJECTIVES Chronic rhinosinusitis with nasal polyps (CRSwNP), which is characterized by partial loss of smell (hyposmia) or total loss of smell (anosmia), is commonly associated with asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). CRSwNP worsens disease severity and quality of life. The objective of this real-world study was to determine whether biological treatments prescribed for severe asthma can improve olfaction in patients with CRSwNP. A further objective was to compare the improvement in in olfaction in N-ERD and non-N-ERD subgroups. METHODS We performed a multicenter, noninterventional, retrospective, observational study of 206 patients with severe asthma and CRSwNP undergoing biological treatment (omalizumab, mepolizumab, benralizumab, or reslizumab). RESULTS Olfaction improved after treatment with all 4 monoclonal antibodies (omalizumab [35.8%], mepolizumab [35.4%], reslizumab [35.7%], and benralizumab [39.1%]), with no differences between the groups. Olfaction was more likely to improve in patients with atopy, more frequent use of short-course systemic corticosteroids, and larger polyp size. The proportion of patients whose olfaction improved was similar between the N-ERD (37%) and non-N-ERD (35.7%) groups. CONCLUSIONS This is the first real-world study to compare improvement in olfaction among patients undergoing long-term treatment with omalizumab, mepolizumab, reslizumab, or benralizumab for severe asthma and associated CRSwNP. Approximately 4 out of 10 patients reported a subjective improvement in olfaction (with nonsignificant differences between biologic drugs). No differences were found for improved olfaction between the N-ERD and non-N-ERD groups.
Collapse
Affiliation(s)
- B Barroso
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - M Valverde-Monge
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - I Alobid
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain
| | - J M Olaguibel
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Allergy Department, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - M J Rial
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Allergy Department, Hospital Juan Canalejo, A Coruña, Spain
| | - S Quirce
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Department of Allergy, La Paz University Hospital, Madrid, Spain.,Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - E Arismendi
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.,Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - P Barranco
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Department of Allergy, La Paz University Hospital, Madrid, Spain.,Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - D Betancor
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - I Bobolea
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.,Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - B Cárdaba
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - M J Cruz Carmona
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology Department, Hospital Universitari Vall d´Hebron, Barcelona, Spain
| | - E Curto
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - J Domínguez-Ortega
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Department of Allergy, La Paz University Hospital, Madrid, Spain.,Hospital La Paz Institute for Health Research (IDIPAZ), Madrid, Spain
| | - F J González-Barcala
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain
| | - C Martínez-Rivera
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology Department, Hospital Germans Trias i Pujol, Badalona, Spain
| | | | - X Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology Department, Hospital Universitari Vall d´Hebron, Barcelona, Spain.,Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - C Picado
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.,Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Plaza
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - J M Rodrigo Muñoz
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - L Soto-Retes
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Pulmonology and Allergy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Barcelona, Spain
| | - A Valero
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.,Allergy Unit and Severe Asthma Unit, Pulmonology and Allergy Department, Hospital Clínic, Barcelona, Spain
| | - V Del Pozo
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
| | - J Mullol
- CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain.,Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain
| | - J Sastre
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
17
|
Barroso B, Torrico-Hatami S, Otal-Buesa M, Bernaola J, Haro R. Macular Amyloidosis in an Atopic Patient After Aeroallergen Immunotherapy. J Allergy Clin Immunol Pract 2022; 10:3018-3019. [PMID: 36057531 DOI: 10.1016/j.jaip.2022.07.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 07/21/2022] [Accepted: 07/22/2022] [Indexed: 06/15/2023]
Affiliation(s)
- Blanca Barroso
- Department of Allergy, Fundación Jiménez Díaz, Madrid, Spain; CIBERES, Instituto de Salud Carlos III, Madrid, Spain.
| | | | | | - Jaime Bernaola
- Department of Allergy, Fundación Jiménez Díaz, Madrid, Spain
| | - Rosario Haro
- Department of Dermatology, Fundación Jiménez Díaz, Madrid, Spain
| |
Collapse
|
18
|
Betancor D, Olaguibel JM, Rodrigo‐Muñoz JM, Arismendi E, Barranco P, Barroso B, Bobolea I, Cárdaba B, Cruz MJ, Curto E, Del Pozo V, González‐Barcala F, Martínez‐Rivera C, Mullol J, Muñoz X, Picado C, Plaza V, Quirce S, Rial MJ, Soto L, Valero A, Valverde‐Monge M, Sastre J. How reliably can algorithms identify eosinophilic asthma phenotypes using non-invasive biomarkers? Clin Transl Allergy 2022; 12:e12182. [PMID: 36000018 PMCID: PMC9391921 DOI: 10.1002/clt2.12182] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 06/06/2022] [Accepted: 07/01/2022] [Indexed: 11/14/2022] Open
Abstract
Background and Aims Asthma is a heterogeneous respiratory disease that encompasses different inflammatory and functional endophenotypes. Many non‐invasive biomarkers has been investigated to its pathobiology. Heany et al proposed a clinical algorithm that classifies severe asthmatic patients into likely‐eosinophilic phenotypes, based on accessible biomarkers: PBE, current treatment, FeNO, presence of nasal polyps (NP) and age of onset. Materials and Methods We assessed the concordance between the algorithm proposed by Heany et al. with sputum examination, the gold standard, in 145 asthmatic patients of the MEGA cohort with varying grades of severity. Results No correlation was found between both classifications 0.025 (CI = 0.013–0.037). Moreover, no relationship was found between sputum eosinophilia and peripheral blood eosinophilia count in the total studied population. Discussion and Conclusion In conclusion, our results suggest that grouping the biomarkers proposed by Heany et al. are insufficient to diagnose eosinophilic phenotypes in asthmatic patients. Sputum analysis remains the gold standard to assess airway inflammation.
Collapse
|
19
|
Betancor D, Valverde-Mongue M, Gomez-Lopez A, Barroso B, Ruete L, Olaguibel JM, Sastre J. Evaluation of fractional exhaled nitric oxide during SARS-CoV-2 infection. J Investig Allergol Clin Immunol 2021; 32:301-303. [PMID: 34755657 DOI: 10.18176/jiaci.0762] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D Betancor
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M Valverde-Mongue
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - A Gomez-Lopez
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - B Barroso
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - L Ruete
- Eversens, Pamplona, Navarra, Spain
| | - J M Olaguibel
- Allergy Department, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain.,CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - J Sastre
- Allergy Department, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain.,CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
20
|
Baptista-Serna L, Rodrigo-Muñoz JM, Mínguez P, Valverde-Monge M, Arismendi E, Barranco P, Barroso B, Bobolea I, Cañas JA, Cárdaba B, Cruz MJ, Curto E, Domínguez J, García-Latorre R, González-Barcala FJ, Martínez-Rivera C, Mullol J, Muñoz X, Olaguibel JM, Picado C, Plaza V, Quirce S, Rial MJ, Sastre B, Soto L, Valero A, Pozo VD, Sastre J. Anxiety and BMI affect asthma control: data from a prospective Spanish cohort. J Allergy Clin Immunol Pract 2021; 10:863-866.e1. [PMID: 34673289 DOI: 10.1016/j.jaip.2021.10.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 09/15/2021] [Accepted: 10/04/2021] [Indexed: 11/17/2022]
Affiliation(s)
| | - José Manuel Rodrigo-Muñoz
- Department of Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Pablo Mínguez
- Department of Genetics and Genomics, IIS Fundación Jiménez Díaz, Madrid, Spain; Bioinformatics Unit, IIS Fundación Jiménez Díaz, Madrid, Spain; Centre for Biomedical Network Research on rare diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | | | - Ebymar Arismendi
- Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic; IDIBAPS; Universitat de Barcelona. Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Pilar Barranco
- Department of Allergy, Hospital La Paz-Institute for Health Research (IdiPAZ), Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Blanca Barroso
- Department of Allergy, IIS-Fundación Jiménez Díaz, Madrid, Spain
| | - Irina Bobolea
- Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic; IDIBAPS; Universitat de Barcelona. Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - José Antonio Cañas
- Department of Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Blanca Cárdaba
- Department of Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - María Jesús Cruz
- Departamento de Biología Celular, Fisiología e Inmunología, Universitat Autónoma de Barcelona, Barcelona, Spain; Servicio de Neumología, Hospital Vall d'Hebron, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Elena Curto
- Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institute of Sant Pau Biomedical Research (IBB Sant Pau), Universitat Autònoma de Barcelona. Department of Medicine, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Javier Domínguez
- Department of Allergy, Hospital La Paz-Institute for Health Research (IdiPAZ), Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Raquel García-Latorre
- Department of Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Francisco J González-Barcala
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain; Department of Respiratory Medicine, University Hospital of Santiago de Compostela (CHUS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Carlos Martínez-Rivera
- Servicio de Neumología, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Joaquim Mullol
- Rhinology Unit & Smell Clinic, ENT Department; Clinical and Experimental Respiratory Immunoallergy (IDIBAPS); Universitat de Barcelona. Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Xavier Muñoz
- Departamento de Biología Celular, Fisiología e Inmunología, Universitat Autónoma de Barcelona, Barcelona, Spain; Servicio de Neumología, Hospital Vall d'Hebron, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - José María Olaguibel
- Severe asthma unit, Department of Allergy, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - César Picado
- Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic; IDIBAPS; Universitat de Barcelona. Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Vicente Plaza
- Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institute of Sant Pau Biomedical Research (IBB Sant Pau), Universitat Autònoma de Barcelona. Department of Medicine, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Santiago Quirce
- Department of Allergy, Hospital La Paz-Institute for Health Research (IdiPAZ), Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Manuel J Rial
- Department of Allergy, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
| | - Beatriz Sastre
- Department of Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Lorena Soto
- Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institute of Sant Pau Biomedical Research (IBB Sant Pau), Universitat Autònoma de Barcelona. Department of Medicine, Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Antonio Valero
- Allergy Unit & Severe Asthma Unit, Pneumonology and Allergy Department, Hospital Clínic; IDIBAPS; Universitat de Barcelona. Barcelona, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Victoria Del Pozo
- Department of Immunology, IIS-Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| | - Joaquín Sastre
- Department of Allergy, IIS-Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III Madrid, Spain
| |
Collapse
|
21
|
Valverde-Monge M, Barroso B, Ortega-Martin L, Betancor D, Santillan J, Villacampa JM, Sastre J. Exploring adherence to treatment in nasal polyposis. J Investig Allergol Clin Immunol 2021; 32:299-301. [PMID: 34489223 DOI: 10.18176/jiaci.0752] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M Valverde-Monge
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain, CIBERES, Instituto de Salud Carlos III, Spain
| | - B Barroso
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, SpainDepartment of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain, CIBERES, Instituto de Salud Carlos III, Spain
| | - L Ortega-Martin
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - D Betancor
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J Santillan
- Department of Otorhinolaryngology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J M Villacampa
- Department of Otorhinolaryngology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - J Sastre
- Department of Allergy, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.,Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain, CIBERES, Instituto de Salud Carlos III, Spain
| |
Collapse
|
22
|
Valverde-Monge M, Cañas JA, Barroso B, Betancor D, Ortega-Martin L, Gómez-López A, Rodríguez-Nieto MJ, Mahíllo-Fernández I, Sastre J, Del Pozo V. Eosinophils and Chronic Respiratory Diseases in Hospitalized COVID-19 Patients. Front Immunol 2021; 12:668074. [PMID: 34149705 PMCID: PMC8208034 DOI: 10.3389/fimmu.2021.668074] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Accepted: 05/17/2021] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Studies on the role of eosinophils in coronavirus disease 2019 (COVID-19) are scarce, though available findings suggest a possible association with disease severity. Our study analyzes the relationship between eosinophils and COVID-19, with a focus on disease severity and patients with underlying chronic respiratory diseases. METHODS We performed a retrospective analysis of 3018 subjects attended at two public hospitals in Madrid (Spain) with PCR-confirmed SARS-CoV-2 infection from January 31 to April 17, 2020. Patients with eosinophil counts less than 0.02×109/L were considered to have eosinopenia. Individuals with chronic respiratory diseases (n=384) were classified according to their particular underlying condition, i.e., asthma, chronic pulmonary obstructive disease, or obstructive sleep apnea. RESULTS Of the 3018 patients enrolled, 479 were excluded because of lack of information at the time of admission. Of 2539 subjects assessed, 1396 patients presented an eosinophil count performed on admission, revealing eosinopenia in 376 cases (26.93%). Eosinopenia on admission was associated with a higher risk of intensive care unit (ICU) or respiratory intensive care unit (RICU) admission (OR:2.21; 95%CI:1.42-3.45; p<0.001) but no increased risk of mortality (p>0.05). CONCLUSIONS Eosinopenia on admission conferred a higher risk of severe disease (requiring ICU/RICU care), but was not associated with increased mortality. In patients with chronic respiratory diseases who develop COVID-19, age seems to be the main risk factor for progression to severe disease or death.
Collapse
Affiliation(s)
| | - José A. Cañas
- Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - Blanca Barroso
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Diana Betancor
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | | | - Alicia Gómez-López
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - María Jesús Rodríguez-Nieto
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
- Pulmonology Unit, Hospital Universitario Fundación Jiménez Díaz and Hospital General de Villalba, Madrid, Spain
| | - Ignacio Mahíllo-Fernández
- Epidemiology and Biostatistics Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
| | - Joaquín Sastre
- Allergy Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| | - Victoria Del Pozo
- Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
- CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
23
|
Ortega-Martin L, Betancor D, Barroso B, Valverde-Monge M, Santillan J, Villacampa JM, Sastre J. Where Have All The Nasal Polyposis Gone? J Investig Allergol Clin Immunol 2021; 31:500-502. [PMID: 33574016 DOI: 10.18176/jiaci.0679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - D Betancor
- Department of Allergy, Fundación Jiménez Díaz, Madrid
| | - B Barroso
- Department of Allergy, Fundación Jiménez Díaz, Madrid
| | | | - J Santillan
- Department of Otorhinolaryngology, Fundación Jiménez Díaz, Madrid
| | - J M Villacampa
- Department of Otorhinolaryngology, Fundación Jiménez Díaz, Madrid
| | - J Sastre
- Department of Allergy, Fundación Jiménez Díaz, Madrid.,Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain, CIBERES, Instituto de Salud Carlos III, Spain ORCID 0000-0003-4689-6837
| |
Collapse
|
24
|
Betancor D, Villalobos V, Valverde-Monge M, Barroso B, Sastre J. Exhaled nitric oxide is of limited value in the diagnosis of occupational asthma. J Allergy Clin Immunol Pract 2020; 9:1726-1727.e2. [PMID: 33242627 DOI: 10.1016/j.jaip.2020.09.068] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 09/27/2020] [Accepted: 09/28/2020] [Indexed: 11/29/2022]
Affiliation(s)
- Diana Betancor
- Allergology Service, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación Sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
| | - Victoria Villalobos
- Allergology Service, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación Sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Marcela Valverde-Monge
- Allergology Service, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación Sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Blanca Barroso
- Allergology Service, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación Sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - Joaquin Sastre
- Allergology Service, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación Sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| |
Collapse
|
25
|
Barroso B, Valverde-Monge M, Cañas Jose A, Rodrigo-Muñoz JM, Gonzalez-Cano B, Villalobos-Violan V, Betancor D, Gomez-Cardeñosa A, Vallejo-Chamorro G, Baptista-Serna L, Villalobos-Vilda C, Ortega-Martin L, Gómez-López A, Sanchez-Pernaute O, Romero-Bueno F, Rodriguez-Nieto MJ, Del Pozo V, Sastre J. Prevalence, Characteristics, and Outcome of Asthmatic Patients With Type 2 Diseases in Hospitalized Patients With COVID-19 in Madrid, Spain. J Investig Allergol Clin Immunol 2020; 30:382-384. [PMID: 32554336 DOI: 10.18176/jiaci.0627] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B Barroso
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - M Valverde-Monge
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - A Cañas Jose
- Immunology Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES)
| | - J M Rodrigo-Muñoz
- Immunology Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES)
| | - B Gonzalez-Cano
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - V Villalobos-Violan
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - D Betancor
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - A Gomez-Cardeñosa
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - G Vallejo-Chamorro
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - L Baptista-Serna
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - C Villalobos-Vilda
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - L Ortega-Martin
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - A Gómez-López
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - O Sanchez-Pernaute
- Rheumatology Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - F Romero-Bueno
- Rheumatology Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - M J Rodriguez-Nieto
- Pulmunology Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain
| | - V Del Pozo
- Immunology Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES)
| | - J Sastre
- Allergy Department, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain.,CIBER de Enfermedades Respiratorias (CIBERES)
| | | |
Collapse
|
26
|
Rial MJ, Barroso B, Rodríguez-Bermejo C, Sastre J. Letter regarding "Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment". J Allergy Clin Immunol Pract 2020; 7:753. [PMID: 30717876 DOI: 10.1016/j.jaip.2018.10.055] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2018] [Revised: 09/28/2018] [Accepted: 10/03/2018] [Indexed: 11/17/2022]
Affiliation(s)
- Manuel Jorge Rial
- Department of Allergy, Hospital Universitario Fundación Jimenez Diaz, Instituto de Investigación Sanitaria Fundación Jimenez Diaz (IIS-FJD, UAM), Madrid, Spain; CIBER de enfermedades respiratorias (CIBERES), Instituto de Salud Carlos III, Spain.
| | - Blanca Barroso
- Department of Allergy, Hospital Universitario Fundación Jimenez Diaz, Instituto de Investigación Sanitaria Fundación Jimenez Diaz (IIS-FJD, UAM), Madrid, Spain
| | | | - Joaquín Sastre
- Department of Allergy, Hospital Universitario Fundación Jimenez Diaz, Instituto de Investigación Sanitaria Fundación Jimenez Diaz (IIS-FJD, UAM), Madrid, Spain; CIBER de enfermedades respiratorias (CIBERES), Instituto de Salud Carlos III, Spain
| |
Collapse
|
27
|
Barroso B, Vera-Berrios RN, Rial JM, Fariña-Sabaris MC, Santos LC, Sastre J. Prevalence of Severe Atopic Dermatitis in Adults and Children in a Health Area of Madrid, Spain. J Investig Allergol Clin Immunol 2019; 29:77-79. [PMID: 30785113 DOI: 10.18176/jiaci.0339] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B Barroso
- Allergy Department, University Hospital Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - R N Vera-Berrios
- Allergy Department, University Hospital Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - J M Rial
- Allergy Department, University Hospital Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - M C Fariña-Sabaris
- Dermatology Department, University Hospital Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - L C Santos
- Dermatology Department, University Hospital Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - J Sastre
- Allergy Department, University Hospital Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| |
Collapse
|
28
|
Barroso B. Transcranial Color-coded Sonography to assess Collateral Posterior Pathways in a case of spontaneous Bilateral Carotid Arteries Dissection in the Absence of Ischaemic Event. Ultrasound Int Open 2016; 2:E32-3. [DOI: 10.1055/s-0035-1569331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
29
|
Coomans H, Barroso B, Bertandeau E, Bonnan M, Dakar A, Demasles S, Garraud S, Krim E, Martin-Négrier ML. Mutisme et troubles du comportement aigus révélant un syndrome MELAS. Rev Neurol (Paris) 2011; 167:847-51. [DOI: 10.1016/j.neurol.2011.01.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2010] [Revised: 10/08/2010] [Accepted: 01/17/2011] [Indexed: 11/24/2022]
|
30
|
Durand de Grossouvre N, Rivière JF, Bertandeau E, Bonnan M, Dakar A, Krim E, Barroso B. [Ischemic strokes related to benign primitive cardiac tumours]. Rev Neurol (Paris) 2010; 167:155-9. [PMID: 21185044 DOI: 10.1016/j.neurol.2010.08.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2010] [Revised: 07/15/2010] [Accepted: 08/27/2010] [Indexed: 11/30/2022]
Abstract
BACKGROUND We report three cases of ischemic cardioembolic strokes related to benign primary cardiac tumours (two fibromas and one fibroelastoma). CASE REPORTS This is a retrospective study over a five years period (from December 2004 to December 2009) in a French community hospital. Data on hospital strokes were obtained from the informatics department. Three benign primary cardiac tumours were found as the cause of acute neurological manifestations: a 45-year-old woman with a fibroelastoma revealed by a brain infarction, a 29-year-old man with a myxoma revealed by a transient ischemic attack, and a 46-year-old woman with a myxoma revealed by a brain infarction. Rankin scores performed at least 18 months after cardiac tumour surgery were respectively of 0, 0 and 2. CONCLUSION Our study confirms that this is a rare event even if those tumours seem to have a high embolic potential (myxomas). Anyway, long-term functional outcome seems to be good.
Collapse
Affiliation(s)
- N Durand de Grossouvre
- Service de neurologie, centre hospitalier François-Mitterrand, 4, boulevard Hauterive, 64046 Pau cedex, France
| | | | | | | | | | | | | |
Collapse
|
31
|
Collongues N, Marignier R, Zéphir H, Papeix C, Fontaine B, Blanc F, Rodriguez D, Fleury M, Vukusic S, Pelletier J, Audoin B, Thouvenot E, Camu W, Barroso B, Ruet A, Brochet B, Vermersch P, Confavreux C, de Seze J. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 2010; 75:1084-8. [PMID: 20855851 DOI: 10.1212/wnl.0b013e3181f39a66] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Neuromyelitis optica (NMO) is a rare inflammatory disease. Average age at onset is 35 years. Few data exist on patients with pediatric-onset NMO (p-NMO), with disease onset before age 18 years. We report the clinical and paraclinical features and long-term outcome of patients with p-NMO and compare them with a large adult-onset NMO (a-NMO) cohort. METHODS We performed a retrospective, multicenter study of patients with p-NMO in pediatric and adult medical centers. We identified 125 patients with NMO (12 p-NMO; 113 a-NMO) fulfilling the 2006 criteria. Data were collected using hospital files and standardized assessment forms for NMO. RESULTS Patients with p-NMO were followed up during a mean 19.3 years. Median age at onset was 14.5 years (4.1-17.9) with a female:male ratio of 3:1. Three patients (25%) fulfilled Paty criteria for multiple sclerosis on first brain MRI, including one patient with acute disseminated encephalomyelitis. Median interval between onset and residual Expanded Disability Status Scale (EDSS) score 4 was 20.7 years, score 6 was 26 years, and score 7 was 28.7 years. Median interval between onset and residual visual loss ≤1/10 was 1.3 years. Compared with a-NMO, p-NMO showed a longer time to EDSS scores 4 and 6, largely explained by the severity of the first myelitis in the a-NMO group. Time to first treatment was longer in the p-NMO group (13.1 vs 3.4 years). CONCLUSION Patients with p-NMO can present a diffuse inflammatory process on first brain MRI and have a longer time to disability than patients with a-NMO.
Collapse
Affiliation(s)
- N Collongues
- Department of Neurology, University Hospital of Strasbourg, 1, Place de l'Hôpital, 67091 Strasbourg, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C, Tchikviladzé M, Outteryck O, Vukusic S, Fleury M, Fontaine B, Brassat D, Clanet M, Milh M, Pelletier J, Audoin B, Ruet A, Lebrun-Frenay C, Thouvenot E, Camu W, Debouverie M, Créange A, Moreau T, Labauge P, Castelnovo G, Edan G, Le Page E, Defer G, Barroso B, Heinzlef O, Gout O, Rodriguez D, Wiertlewski S, Laplaud D, Borgel F, Tourniaire P, Grimaud J, Brochet B, Vermersch P, Confavreux C, de Seze J. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010; 74:736-42. [PMID: 20194912 DOI: 10.1212/wnl.0b013e3181d31e35] [Citation(s) in RCA: 158] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND There have been few epidemiologic studies on neuromyelitis optica (NMO) and none used the recent 2006 diagnostic criteria. Here we describe the clinical, laboratory, MRI, and disability course of NMO in a French cohort of 125 patients. METHODS We performed an observational, retrospective, multicenter study. Data were collected from September 2007 through August 2008, corresponding to the endpoint of the study. We identified 125 patients fulfilling the 2006 NMO criteria. Selection was made using hospital files and a specific clinical questionnaire for NMO. RESULTS Mean age at onset was 34.5 years (range 4-66) with a mean disease duration of 10 +/- 7.8 years at the endpoint. The patients were mainly (87%) Caucasian, with a female:male ratio of 3:1. In 90% of cases, the association of optic neuritis, longitudinal extensive myelitis, and a Paty-negative initial brain MRI was sufficient to fulfill the supportive criteria. Eighty-eight percent of patients were treated with immunosuppressive therapies. Median delay from onset to Expanded Disability Status Scale (EDSS) score 4 was 7 years; score 6, 10 years; and score 7, 21 years. The first episode of myelitis was immediately followed by an EDSS score > or = 4 in 37.3% of cases, and a severe residual visual loss was observed in 22% of patients after the first episode of optic neuritis. Multivariate analysis did not reveal any predictors of a poor evolution other than a high number of MRI brain lesions at diagnosis, which were predictive of a residual visual acuity < or = 1/10. CONCLUSIONS Our demographic data provide new data on disability in patients with neuromyelitis optica, most of whom were receiving treatment.
Collapse
Affiliation(s)
- N Collongues
- Department of Neurology, University Hospital of Strasbourg, 67091 Strasbourg, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Tchikviladzé M, Ritleng C, Outteryck O, Vukusic S, Fleury M, Mignot C, Brassat D, Clanet M, Milh M, Ruet A, Lebrun-Frenay C, Camu W, Debouverie M, Créange A, Moreau T, Labauge P, Castelnovo G, Edan G, Lepage E, Defer G, Barroso B, Thouvenot E, Heinzlef O, Gout O, Rodriguez D, Augustin J, Wiertlewski S, Laplaud D, Borgel F, Slassi I, Berroir S, Tourniaire P, Grimaud J, Brochet B, Vermersch P, Confavreux C, de Sèze J. Neuromyélite optique de Devic et patients à haut risqué : enquête rétrospective nationale. Rev Neurol (Paris) 2009. [DOI: 10.1016/s0035-3787(09)70025-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Barroso B, Larrieu J, Morisset C, Dakar A, Mangon H. G - 5 Faisabilité de la thrombolyse aux urgences du CH de Pau (64) : résultats à 2 ans chez 42 patients traités. Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90511-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
35
|
Barroso B, Bertandeau E, Dakar A, Krim E, Larrieu JM. F - 1 Syndrome de Gougerot-Sjögren primitif de localisation neurologique centrale évoluant sur un mode rémittent avec séquelles. Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90833-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
36
|
Dousset V, Brochet B, Deloire MSA, Lagoarde L, Barroso B, Caille JM, Petry KG. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol 2006; 27:1000-5. [PMID: 16687532 PMCID: PMC7975759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
BACKGROUND AND PURPOSE Inflammatory multiple sclerosis (MS) lesions are characterized by microglia activation and infiltration of T cells, B cells, and macrophages across the blood-brain barrier (BBB). In the experimental autoimmune encephalomyelitis (EAE) rat model of MS, previous MR imaging investigations with a new contrast agent ultra-small-particle iron oxide (USPIO) that accumulates in phagocytic cells revealed in vivo the presence of macrophage brain infiltration. The goal of this study was to characterize MS lesions with the use of this contrast agent. METHODS A prospective MR imaging study of 10 patients with MS in acute relapses was achieved by using USPIO and gadolinium. RESULTS Twenty-four hours after USPIO injection, 33 acute MS lesions in 9 patients showed USPIO uptake. Lesions were seen as high signal intensities on T1-weighted images and low signal intensities on T2-weighted images. Gadolinium enhancement was seen in 31 of these lesions in 7 patients. These 7 patients presented 24 gadolinium-enhanced lesions that did not enhance with USPIO. Two patients showed USPIO-enhanced lesions but no gadolinium-enhanced lesions. CONCLUSION Taken together with earlier findings obtained in experimental models or in human stroke, the visualization of macrophage activity in vivo with USPIO characterize a distinct cellular and inflammatory event of the dynamic process of MS lesion formation. The macrophage activity information obtained with USPIO is distinct and complementary to the increased BBB permeability seen with gadolinium.
Collapse
Affiliation(s)
- V Dousset
- University Victor Segalen Bordeaux 2, Centre Hospitalier Universitaire de Bordeaux, Laboratory of Neurobiology of Myelin Diseases, EA 2966 Bordeaux, France
| | | | | | | | | | | | | |
Collapse
|
37
|
Barroso B, Bertandeau E, Zerbib JL, Larribau E, Dakar A, Larrieu JM. [Pseudomigraine with transient neurological deficits and cerebrospinal fluid lymphocytosis]. Rev Neurol (Paris) 2005; 161:1102-5. [PMID: 16288175 DOI: 10.1016/s0035-3787(05)85177-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
INTRODUCTION Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis is a rare syndrome resolving within less than 3 months. CASE REPORT A young 17-year-old woman without previous medical history was admitted to the hospital because of right motor weakness and language disturbances. The symptoms resolved in a few hours and were followed by severe left headaches with important vegetative signs. Several similar episodes were noted in the previous 10 days. Cranial MRI was normal. EEG showed important slowing of the cerebral electrogenesis. More than 250 lymphocytic cells were found at CSF analysis. Outcome was spontaneously favorable, without similar symptoms after 6-month follow-up. CONCLUSION Pseudomigraine with lymphocytic pleocytosis seems to be a particular syndrome of unknown origin. This is an elimination diagnosis, generally with a benign course.
Collapse
Affiliation(s)
- B Barroso
- Service de Neurologie, Centre Hospitalier François Mitterrand, Pau Université.
| | | | | | | | | | | |
Collapse
|
38
|
Deloire MSA, Salort E, Bonnet M, Arimone Y, Boudineau M, Amieva H, Barroso B, Ouallet JC, Pachai C, Galliaud E, Petry KG, Dousset V, Fabrigoule C, Brochet B. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76:519-26. [PMID: 15774439 PMCID: PMC1739602 DOI: 10.1136/jnnp.2004.045872] [Citation(s) in RCA: 146] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
OBJECTIVES To establish the frequency of cognitive impairment in a population based sample of patients with recently diagnosed relapsing-remitting multiple sclerosis (RRMS), and to determine the relation between cognitive abnormalities and the extent of macroscopic and microscopic tissue damage revealed by magnetic resonance imaging (MRI) and magnetisation transfer (MT) imaging. METHODS 58 patients with RRMS consecutively diagnosed in the previous six months in Aquitaine and 70 healthy controls underwent a battery of neuropsychological tests. Lesion load and atrophy indices (brain parenchymal fraction and ventricular fraction) were measured on brain MRI. MT ratio (MTR) histograms were obtained from lesions, normal appearing white matter (NAWM), and normal appearing grey matter (NAGM). Gadolinium enhanced lesions were counted. RESULTS 44 RRMS patients could be individually matched with healthy controls for age, sex, and education. Patients performed worse in tests of verbal and spatial memory, attention, information processing speed, inhibition, and conceptualisation. Measures of attention and information processing speed were correlated with lesion load, mean NAWM MTR, and the peak location of the NAGM MTR histogram in the patients. Multivariate regression analysis showed that lesion load and mean NAWM MTR were among the MR indices that were most significantly associated with impairment of attention and information processing speed in these early RRMS cases. CONCLUSIONS Cognitive impairment appears to be common in the early stages of RRMS, mainly affecting attention, information processing speed, memory, inhibition, and conceptualisation. The severity of these deficits reflects the extent of the lesions and the severity of tissue disorganisation outside lesions.
Collapse
Affiliation(s)
- M S A Deloire
- EA 2966 Neurobiology of Myelin Disorders Laboratory, University Victor Segalen, case 78, 146 rue Léo Saignat, 33076 Bordeaux cedex, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Barroso B, Bigou P, Martin K, Lippa A, Chabouni L, Dakar A, Larribau E, Larrieu JM. Angiopathie cérébrale réversible du post-partum imputable à la bromocriptine. Rev Neurol (Paris) 2004; 160:1191-3. [PMID: 15602366 DOI: 10.1016/s0035-3787(04)71165-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Postpartum is known to be an important risk factor for stroke. Bromocriptine may induce cerebral angiopathy. CASE DESCRIPTION We report the case of a 26-year-old postpartum woman who presented with headaches, seizures, hypertension and acute renal failure eight days after the beginning of a treatment with bromocriptine prescribed for lactation suppression. Brain MRI and MR angiogram excluded cortical vein thrombosis and revealed multiple abnormal areas of increased signal in the cortex with segmental arterial narrowings of intracranial vasculitis. The patient completely recovered within one week after drug withdrawal. Biological and radiological abnormalities were also reversible. Following the chronology bromocriptine was most likely responsible for this adverse cerebral and systemic event. CONCLUSION Clinicians should be aware of bromocripine-related postpartum cerebral angiopathy, a rarely described but serious complication of bromocriptine used to prevent postpartum breast engorgement.
Collapse
Affiliation(s)
- B Barroso
- Service de Neurologie, Centre Hospitalier François Mitterrand, Pau.
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Barroso B. [Reversible parkinsonism induced by prolonged treatment with valproate]. Therapie 2002; 57:410-1. [PMID: 12422564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
|
41
|
Coman I, Barroso B, Sawan B, Brochet B. [Signet-ring cell carcinomatous meningitis complicating esophageal neoplasia]. Rev Neurol (Paris) 2001; 157:1539-41. [PMID: 11924452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
Leptomeningeal invasion is an uncommon complication of systemic solid cancers. We describe a patient with such an infiltration caused by a signet-ring cells esophageal adenocarcinoma. The diagnosis required repeated cytologic examinations of cerebrospinal fluid while clinical signs and biological data were not conclusive, mimicking acute infectious meningoencephalitis. Magnetic resonance imaging was highly contributive in establishing the diagnosis. Nevertheless this is a very rare complication of esophageal cancers as this metastatic location occurred in advanced stages of the disease and as we know the poor prognosis of those cancers.
Collapse
Affiliation(s)
- I Coman
- Service de neurologie A, CHU Pellegrin, Place Amélie Raba-Léon, 33076 Bordeaux
| | | | | | | |
Collapse
|
42
|
Barroso B. [Illness management modalities]. Rev Neurol (Paris) 2001; 157:1175-83. [PMID: 11787353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Multiple sclerosis (MS) is the most common neurological disease disabling young adults. Patients with MS experience symptoms in an unpredictable pattern over years or decades. The doctor/patient relationship in MS, beginning with the announcement of the diagnosis has to grow stronger with a clear structured information following from the many available studies of the medical literature. This is all the more welcome since the introduction of a new generation of disease-modifying agents which has a radical effect on the management of the condition. This management of MS must also concentrate on symptom relief, palliative care and complementary therapies including rehabilitation when a disability occurs. Nowadays, a quality health service for people with MS need to be intimately involved in the long-term care of a disease which has frequently a social and occupational impact. Physicians of several disciplines, primary medical care, social service and nurses should work as an integrated medical network model focusing on the patient and his family.
Collapse
Affiliation(s)
- B Barroso
- Service de Neurologie A, CHU Pellegrin, place Amélie Raba Léon, 33076 Bordeaux.
| |
Collapse
|
43
|
Krim E, Barroso B. [Psychiatric disorders treated with clozapine in a patient with Wilson's disease]. Presse Med 2001; 30:738. [PMID: 11360740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/16/2023] Open
|
44
|
Barroso B, Nicolas C, Brochet B. [Regressive posterior leukoencephalopathy revealing systemic arterial hypertension]. Presse Med 2001; 30:120. [PMID: 11225483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
|